Menu
Recruiting NCT06296875

The Krill Ageing Muscle Mechanisms (KAMM) Study

No phase Interventional Sarcopenia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Vegetable oil, Krill oil.
Who it may be relevant to
Registry conditions: Sarcopenia. Basic parameters: 65 years — 90 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United Kingdom
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Uncovering the Mechanisms Through Which Krill Oil Increases Muscle Function in Older Adults.

Overview

This study aims to determine the mechanisms via which krill oil supplementation increases muscle strength and whether this translates to improvements in gait and functional characteristics in older adults. The studies we will carry out will establish, in healthy older adults, the effects of 6 months of supplementation with krill oil Objective 1) Muscle structure and function Hypothesis: Krill oil supplementation will increase muscle size and strength alongside positive changes in muscle architecture (pennation angle and fascicle length). Objective 2) Neuromuscular control and central nervous system (CNS) function Hypothesis: Krill oil supplementation will improve Neuromuscular Junction (NMJ) transmission stability and increase central drive and intramuscular coherence, as a measure of muscle synergy. Objective 3) Gait and functional characteristics Hypothesis: Krill oil supplementation will improve gait and functional characteristics.

Interventions

  • Dietary supplement Vegetable oil
    mixed vegetable oil
  • Dietary supplement Krill oil
    Krill oil

Primary outcome measures

  • Grip strength [Time frame: Change from baseline to 24 weeks]
  • Neuromuscular junction transmission instability [Time frame: Change from baseline to 24 weeks]
  • Gait speed [Time frame: Change from baseline to 24 weeks]
Secondary outcome measures (12)
  • Knee extensor maximal torque [Time frame: Change from baseline to 24 weeks]
  • Vastus lateralis muscle cross sectional area [Time frame: Change from baseline to 24 weeks]
  • Vastus lateralis pennation angle [Time frame: Change from baseline to 24 weeks]
  • Vastus lateralis fascicle length [Time frame: Change from baseline to 24 weeks]
  • Erythrocyte fatty acid composition [Time frame: Change from baseline to 24 weeks]
  • Knee extensor force steadiness [Time frame: Change from baseline to 24 weeks]
  • Vastus lateralis motor unit conduction velocity [Time frame: Change from baseline to 24 weeks]
  • Vastus lateralis and vastus medialis intramuscular coherence [Time frame: Change from baseline to 24 weeks]
  • Hand flexor muscles intermuscular coherence [Time frame: Change from baseline to 24 weeks]
  • Cortico-muscular coherence between sensory motor cortex and hand extensor muscles [Time frame: Change from baseline to 24 weeks]
  • Femoral Nerve Stimulation [Time frame: Change from baseline to 24 weeks]
  • Transcranial Magnetic Stimulation (TMS) [Time frame: Change from baseline to 24 weeks]

Eligibility criteria

Inclusion criteria

  • body mass index (BMI) </= 30 kg/m2
  • Age >/= 65 years
  • Capacity to consent
  • Living within the Glasgow area

Exclusion criteria

  • Diabetes mellitus
  • Severe cardiovascular disease
  • Seizure disorders
  • Uncontrolled hypertension (>150/90mmHg)
  • Active cancer or cancer that has been in remission <5 years
  • Participation in any resistance exercise training within the last 6 months
  • Impairments which may limit ability to perform assessments of muscle function
  • Dementia
  • Fish/shellfish allergy
  • Taking medication known to affect muscle (e.g. steroids, Selective serotonin reuptake inhibitors) or anticoagulants (e.g. warfarin)
  • Taking omega-3 supplements in the last 3 months
  • Regularly consuming 1 or more portions of oily fish per week
  • Not able to understand English

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Prevention

Study locations

United Kingdom · 1 center
  • University of Glasgow — Glasgow

Identifiers

NCT: NCT06296875 · KAMM

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗